GLUE Crosses Above Average Analyst Target
August 24, 2021 at 08:23 AM EDT
In recent trading, shares of Monte Rosa Therapeutics Inc (GLUE) have crossed above the average analyst 12-month target price of $36.00, changing hands for $36.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..